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i
Summary: Immunoluminometric assays were developed for apolipoproteins A-I, B, C-II (äs the apolipoprotein
C-II: apolipoprotein B complex), apolipoprotein(a) and lipoprotein(a). The assays were evaluated clinically and
methodologically. The results for apolipoprotein A-I, apolipoprotein B and lipoprotein(a) were compared with those
obtained by turbidimetric assays. No comparison was possible for apolipoprotein C-II.
Sample predilution was necessary for apolipoprotein A-I, apolipoprotein B, apolipoprotein(a) and lipoprotein(a).
Not all antibody combinations gave rise to assays with acceptable recovery rates. This was especially the case for
lipoprotein(a).
These assays for apolipoprotein(a) and lipoprotein(a) had relatively low detection limit (< 5 mg/1) and measuring
ranges up to 800 mg/1 (using a 1: 10 sample dilution), and were suitable for routine use, especially for longer series.
Assay times were all less than 3 h, each assay using the streptavidin-biotin techniqüe and being based on a coated-
ball technology.
The median intra-assay coefficients of Variation for all assays lay between 2.9 and 5.9% in the ränge of interest,
expressed in terms of precision profiles. Inter-assay (im)precision lay between 6.2 and 12.2%, calculated in the
accepted way.
Correlations between turbidimetric and immunoluminometric assays for apolipoprotein A-I and apolipoprotein B
were statistically acceptable, älthough the correlation coefficients were mediocre (apolipoprotein A-I - r = 0.65,
apolipoprotein B — r = 0.83) and the slope of the regressioii line differed from unity. This was most probably due
to standardisation and differences in assay design (one^-site competitive versus two-site immunometric assays).
The correlation between the turbidimetric and immunoluminometric assays for lipoprotein(a) (r = 0.87) and apo-
lipoprotein(a) (r = 0.89) were good, älthough again, the slope of the regression line differed from unity, which was
probably not due to free apolipoprotein(a) but to serum matrix effects, äs the same Standard was used in both assays.
The assays were suitable for routine use,Tespecially when longer series were run. The costs were considerably lower
than those for turbidimetric determinations. The high dilution factor for apolipoprotein A-I (up to l : 2000) and
apolipoprotein B (up to l : 1000) could be seen äs a disadvantage of the immunoluminometric assays.
Introduction has improved the armamentarium available for the sur-
veillance, prevention and combatting of atherosclerosis
The introduction of apolipoprotein determination in ad- and coronary heart disease (1-10). Lipoprotein(a) has
dition to the "classical" lipid metabolism quantities, such been shown to be an important independent marker for
äs triacylglycerols and different cholesterol fractions, atherosclerosis; itisclosely related to plasminogen (11-
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15), thus providing a possible link between lipid metab-
olism and haemostaseology.
Most methods for determination of apolipoproteins are
based on turbidimetry or nephelometry, äs the relatively
high concentrations in blood do not necessarily demand
methods with a very low detection limit. The determi-
nation of lipoprotein(a) using turbidimetry or nephelo-
metry has proved problematic with regard to sample
type (serum or plasma) and reproducibility.
Immunometric technology allows the specific determi-
nation of defined apolipoproteins, äs well äs enabling
the determination of particles containing different apo-
lipoproteins. The main disadvantage of the method is the
dilution Step often needed prior to assay. This is com-
pensated by the application of the method to long series,
for example in screening procedures. This technology
provides a reliable and specific quantification of analytes
that are present in blood in low concentrations, in the
present case apolipoprotein C-II complexed with apo-
lipoproteinN.B.
All assays are based on commercially availäble reagents
and can be set up in any laboratory with suitable measur-
ing equipment. Since the methods use biotinylated anti-
bodies and labelled streptavidin, they can also be ad-




Antibodies were purchased from the following sources:
Dako, Hamburg, Germany,
Immuno, Heidelberg, Germany,
Atlantic Antibodies (ATAB) (Serva), Heidelberg, Germany,
Boehringer-Mannheim, Mannheim, Germany,
Calbiochem-Novabiochem, Bad Soden, Germany.
The combination and source of the antibodies for each assay is
given below.
Standard and control materials were obtained from Boehringer-
Mannheim, Immuno, Behringwerke, Marburg a.d.L., Germany,
Röche Diagnostics, Grenzach-Wyhlen, Germany and Dako.
Amidocaproylbiotin N-hydroxysuccinimide was purchased from
Sigma, Deisenhofen, Germany. Streptavidin was obtained from
Biomol, Hamburg, Germany. 9-[N-(4-aminobutyl)-N-ethyl] amino-
benzo(f)phthalazine 1,4 (2H,3H) dione (ABEN) was synthesised in
the Institute for Biochemical Endocrinology of the Medical Univer-
sity of Lübeck.
Polystyrene balls (6.4 mm diameter) were obtained from Sphero-
tech Kugeln GmbH, Fulda, Germany.
Buffer substances were purchased from Merck, Darmstadt, Germ-
aony or from Sigma.
Methods
The biotinylation of antibodies and labelling of streptavidin with
ABEN was carried out äs previously described (16, 17).
Tab. l Assay scheme for the immunoluminornetric determination
of apolipoproteins.
10 sample (neat for apolipoprotein C-II, or diluted for apolipo-
protein A-I, apolipoprotein B and (apo)lipoprotein(a))
200 assay buffer
l antibody coated ball (anti apolipoprotein C-II, anti apolipoprotein
A-I, anti apolipoprotein B or anti apolipoprotein(a))
Incubate on horizontal shaker (170 min""1) for 60 min
Wash with 2 X 5 ml demineralised water
200 biotinylated antibody (anti apolipoprotein A-I, anti apolipo-
protein B or anti apolipoprotein(a))
Incubate and wash äs above
200 streptavidin-ABEN corijugate
Incubate for 30 min and wash with 3 X 5 ml demineralised water.
*) Transfer ball to measuring cuvette, add 300 catalase, load
luminometer and initiate reaction with 300 alkaline peroxide,
integrating the light signal over 4 seconds.
*) Füll details of the reagents for luminometry have beeri pub-
lished in detail elsewhere — see I.e. (16, 17).
The assay scheme was the same for all analytes and is shown in
table l. Comparative methods were carried out on the Cobas MIRA
(Röche Diagnostics) using turbidimetric methodology. The Stan-
dards and antiserum used were from imrnuno for lipoprotein(a),
and from Röche for apolipoprotein A-t and B for turbidimetry. The
Standards for all five immunoluminornetric assays were all from
Immuno.
The antibody combinations for the immunoluminornetric assays
developed were äs follows:
Apolipoprotein A-I: Solid phase and biotinylated, Dako (Code
No. Q 496).
Apolipoprotein B: Solid phase and biotinylated, Dako (Code No.
Q 497).
Apolipoprotein C-II: Solid phase, Calbiochem anti-apolipoprotein
C-II, biotinylated anti-apolipoprotein B, DAKO (Code Q-497).
Lipoprotein(a): Solid phase, Dako anti-lipoprotein(a) (Code No.
Q023), biotinylated Dako anti-apolipoprotein-B (Code No.
Q 497).
Apolipoprotein(a): Solid phase, Dako anti-lipoprotein(a) (Code No.
Q 023), biotinlated, Immuno anti-lipoprotein(a). Böth antibodies
were raised against apolipoprotein(a).
Apolipoprotein A-I
The best results were obtained with the combination of the anti-
bodies shown above. The sample was assayed at dilutions of
l : 500, l : 1000 and l : 2000. the Standard curve covered the con-
centration ränge 0.125-2 mg/1 (effective ränge up to 4 g/l). The
Standard had been calibrated against the proposed WHO Standard
(18—20) and was supplied by immuno.
Apolipoprotein B
The combination of antibodies was best äs shown above. The Stan-
dard had been calibrated against the proposed WHO Standard and
eovered the ränge 0.125-4 mg/1 (effective ränge up to 4 g/l).
Samples were diluted l : 250, : 500 and l : 1000 before being
assayed. The same Standard was used'as for apolipoprotein A-l.
» »
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Apolipoprotein C-U: Apolipoprotein B
Samples were assayed neat using a serum calibrator for apolipo-
protein C-II supplied by Immuno. The Standard curve covered the
ränge 3.5-105 mg/1.
Lipoprotein(a)
The Standard used was for apolipoprotein(a) below, the specificity
of the assay being determined by the use of anti-lipoprotein(a) on
the solid phase and anti-apolipoprotein B äs Sandwich partner.
Samples were dituted 1:10 and l : 50 before assay.
Apolipoprotein (a)
Samples were assayed using a l : 10 and l : 50 dilution using a
Standard curve which covered the ränge 0-80 mg/l (effective
ränge 0-4000 mg/1). The Standard material was from Immuno.
The antibody combination shown above was the only one in which
samples diluted linearly. The hope that firee apolipoprotein(a) could
be estimated from the diflference between apolipoprotein(a) and
lipoprotein(a) was not realisable due to the unknown airiount of
free apolipoprotein(a) in the Standard used (Information from Im-
muno).
Statistics
Non-parametric statistics were used throughout and correlations
were performed with the Spearman rank correlation method. The
median was used äs the marker of central tendency and relevant
percentiles for the ränge, äs the distribution of apolipoprotein(a)
and lipoprotein(a) concentrations was highly skewed (mean: med-
ian > 2.5).
Results and Discussion
Tables 2a-2b show quality assessment data for all five
assays. The results of geometric dilution of selected
samples are given in tables 3a and 3b.
The results show the large measuring ränge of the immu-
noluminometric assays, which allows very low concen-
trations of apolipoprotein C-II: apolipoprotein B com^
plexes to be measured. Those patients presenting with
metabolic disturbances, either with very low levels of
this analyte (5) or with deficient lipoprotein lipase can
be diagnosed reliäbly.
The precision of the assays is acceptable, älthough the
accuracy, äs far äs this can be measured, must be ques-
tioned for the turbidimetric assay, especially in lipaemic
sera. The relatively high coefficients of Variation for the
immunoluminometric assays for apolipoprotein % A-I and
apolipoprotein B are due to the large dilution factors
coupled with the small sample volüme.
Figure l a shows the correlation between the turbidi-
metric method and the immunoluminometric assay in 92
sera from dialysis patients for apolipoprotein . Figure
Ib shows the same for apolipoprotein B. Correlations
between the nephelömetric assay for lipoprotein(a) and
the immunoluminometric assays for apolipoprotein(a)
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and lipoprotein(a) are shown in figures Ic and Id, re-
spectively. Figure le shows the correlation and between
both immunoluminometric assays.
No attempt was made to determine a reference ränge for
healthy adults for any of the apolipoproteins, since there
is an ongoing debate äs to whether values for single
apolipoproteins have any significance. From the corre-
lation studies it can be seen that the assays presented
here do not give very different results from the estab-
lished routine serum nephelömetric assay for lipo-
protein(a). The results for apolipoproteins A-I and B
were not äs good.
The assays for apolipoproteins A-I, B, and C-II:B show
a linear dilution pattern, showing that Standards and
samples behave in a similar way. Serum matrix effects
were not apparent, but this may be due to the low con-
centrations of serum proteins, especially in the assays
for apolipoprotein A-I and apolipoprotein B. The results
of geometric dilution of selected samples for apolipo-
protein(a) and lipoprotein(a) are given in table 3b. Stab-
ility studies for lipoprotein(a) and apolipoprotein(a) are
shown in figure 2. Figure 3 shows the comparison be-
tween serum and EDTA-plasma lipoprotein(a) in 20
patients, with concentrations throughout the expected
measuring ränge. Table 3b shows that not all sera dilute
out äs expected, which may reflect the different immu-
noreactivity of the small and large lipoprotein(a) mol-
ecules.
The results show that the immunoluminometric assays
have a wide measuring ränge, which allows very low
concentrations of lipoprotein(a) and apolipoprotein(a) to
be measured.
The precision of the assays is acceptable, älthough the
accuracy, äs far äs this can be measured, must be ques-
tioned for the nephelömetric assay, especially in lipae-
mic sera. The nephelömetric method often gave spurious
results ranging from "under the detection limit of the
assay'' (due to the high extinction of the sample before
reaction), to non-linear dilution curves; both effects
were observed in lipaemic sera, and were not present
in the immunoluminometric assays. The nephelömetric
assay was not able to measure lipoprotein(a) in plasma,
all values being above 1000 mg/1. These findings point
to the necessity of analysing serum when using nephelö-
metric methods. Figure 3 shows that the immunolumino-
metric methods can be applied to serum or plasma.
The stäbility of lipoprotein(a) allows samples to be
stored at 4 °C, samples stored in this way usually being
stable for several weeks (fig. 2). Commercial control
sera could be stored at 4 °C without loss of immunoreac-
tive apolipoprotein(a) or lipoprotein(a). These obser-
vations are in accordance with those of Gllleiy et al.
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Tab. 2b Standard curve and quality
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(21), who used a kinetic nephelometric assay, and März
et al. (22) who used immunometric
topic and enzyme labelling, both
no loss of immunoreactivity in






a three week period.
The prediluted Standard curve for (apo)lipoprotein(a)
(1:10 dilution) in assay buffer is stable at 4 °C for at
least 10 days, so that Standards can be prepared once a
week. Prediluted sera (1 : 10) can also be stored at 4 °C
for at least a week without noticeable changes in the
immunoreactivity of (apo)lipoprotein(a). When these
Standards or samples were stored at higher dilutions than
1 : 500 there was a loss of immunoreactivity after 7-10
days at 4 °C. No advantage was gained by storing the
diluted samples/standards at -20 or -30 °C.
The excellent correlation between the two immunolumi-
nometric assays and the poor correlation between the
nephelometric assay and each of the immunolumino-
metric assays for apolipoprotein(a) and lipoprotein(a) re-
flects the practical problems of nephelometric measure-
ments. The use of robust immunometric assays with sig-
nal detection is to be recommended for the determi-
nation of apolipoprotein(a) and lipoprotein(a) in serum.
The non-concordance of results for apolipoprotein(a)
and lipoprotein(a) is probably not due to free apolipo-
protein(a) i. e. the fraction not bound to apolipoprotein
B-100.
The different serum concentrations found for apolipo-
protein^) and lipoprotein(a) cannot be explained en-
tirely by the presence of free apolipoprotein(a), nor by
a cross-reactivity or displacement of apolipoprotein B-
100 by apolipoprotein B-48 in the binding to the anti-
apolipoprotein B on the solid phase. In view of the fact
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Fig. l Method comparison results.
a) Comparison of the turbidimetric assay (x) with the immunolumi-
nometric assay (y) for apolipoprotein A-I in 92 samples from dialy-
sis patients.
The correlation coefficient r = 0.65.
The regression line equation is: y = 0.73x + 0.14.
b) Comparison of the turbidimetric assay (x) with the immunolumi-
nometric assay (y) for apolipoprotein B.
The correlation coefficient r = 0.84.
The regression line equation is: y = 0.76x + 0.26.
c) Comparison of the nephelometric method for Lp(a) (x) with the
immunoluminometric assay for lipoprotein(a) (y, anti-lipopro-
tein(a) label) on 83 samples.
The correlation coefficient r = 0.888.
The regression line equation is: log (y) = 0.981 log (x) + 0.073..
(21 samples, which lay beiow the detection limit of the nephelo-
metric method, were excluded from the comparison.)
d) Comparison of the nephelometric method for Lp(a) (x) with the
immunoluminornetric assay for lipoprotein(a) (y, anti-apolipopro-
tein B label) on 83 samples. The correlation coefficient r = 0.868.
The regression line equation is: log (y) = l .04 log (x) + 0.005.
(21 samples, which lay below the detection limit of the nephelo-
metric method, were excluded from the comparison.)
e) Comparison of the immunoluminometric 'assays for 4ipopro-
tein(a) using anti-apolipoprotein B label (x) and anti-lipoproteih(a)
label (y) on 104 samples.
The correlation coefficient r == 0.965.
The regression of the equation is: log (y) = 0.894 log (x) H- 0;210.
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Fig. 2 Stability of a serum sample stored at 4 °C over a three
week period. Comparison between results from the nephelometric
method for Lp(a) (*) and the immunoluminometric method for
apolipoprotein(a) (A).
The concentrations of other lipid analytes in this sample were:
cholesterol - 7.8 mmol/l,
triacylglycerols — 0.92 mmol/l,
HDL-cholesterol - 2.5 mmol/l,
LDL-cholesterol - 4.9 mmol/l,








Lipoprotein(a) in serum (ILMA)(mg/l)
10000
Fig. 3 Comparison of lipoprotein(a) in serum and plasma from
20 patients using the immunoluminometric assay.
The correlation coefficient r = 0.993.
The slope of the regression line is: log (y) = 0.998 log (x) + 0.022.
that apolipoprotein B-100 is found in üpoproteiii(a), but
not in apolipoprotein(a), and free apolipoprotein(a) may
be present in serum in different amoimts, the results
should, if anything, be higher for apolipoprotein(a) than
for lipoprotein(a). This was not observed (see fig. le).
The results from the present study agree however with
those ofMärz and coworkers, who found a much greater
discrepancy between plasma lipoprotein(a) and apolipo·-
protein(a) using commercial kits, the slope of the re-
gression line being between 0.34 and 0.54, depending
upon the calculation method (14). As the anti apolipo-
protein(a) antisera are both polyclonal, it is not to be
expected that they are directed against a single epitope,
even when the inanufacturers «täte that they are specific
for apolipoprotein(a), antibodies against plasminogen
having been removed by immunoadsorption. The anti-
bodies are specific for conformational epitopes, which
most probably differ according to the molecular struc-
ture of apolipoprotein(a). The differences in the dilution
patterns of different sera support this theory.
The median concentration of lipoprotein(a) from 147
non-selected hospitalised patients was 136 mg/1 for the
nephelometric method and 179 mg/1 for the immuno-
luminometric assay. The median concentration of apo-
lipoprotein(a) was 151 mg/1 for the same samples. These
values are comparable with those reported by Pantegh-
ini & Pagani (23), who reported a mean of 140 mg/1 for
healthy individuals for an immunoluminometric assay
for lipoprotein(a). The comparison of values from differ-
ent methods for lipoprotein(a) is problematic äs it de-
pends upon the material used for standardisation.
The immunometric assays are better suited to the
measurement of lipoprotein(a) and apolipoprotein(a), äs
they are designed to measure the molecule specifically
and are not influenced by factors such äs lipaemia and
the presence of coagulation factors, both of which may
influence nephelometric or turbidometric assays. The
disadvantage of the immunometric assays is the need for
dilution of the sample, although this may dilute out any
adverse serum-matrix effects that may be present. The
assays are suitable for partial automation and are capable
of processing severäl hundred samples per day, a point
worth noting when carrying out epidemiological studies
or when screening large groups.
The quality assessment is acceptable in terms of inter-
and intra-assay precision. The question of accuracy is
still open, due to the absence of an accepted inter-
national reference preparation or Standard. The mic-
roheterogeneity of lipoprotein(a) and the different gen-
etic variants will make the preparation of a single Stan-
dard difficult, especially if the antibodies used only
recognise certain genetic variants or conformational epi-
topes of apolipoprotein(a) (24). The knowledge of anti-
body specificity is important in the determination of
lipoprotein(a), so that the different forms of the lipo-
protein(a) molecule can quantified separately. This
would be helpfiil if the different forms of lipoprotein(a)
were conclusively shown to have different atherogenic
properties.
Further difficulties in assessing the value of studies on
lipoprotein(a) lie in the incorrect use of statistics by
many groups, where, despite the skewed distribution of
values, parametric statistics have been used (25).
The correlation coefficients, although statistically sig-
nificant, were not good, especially for apolipoprotein
A-I, and many reflect the difference in assay design
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(competitivc versus Sandwich methodology) äs well äs
the Standard used and the effect of the sample material
itself. Samples froni dialysis patients were chosen, äs it
is known that serum from such patients often presents
analytical problems, especially in nephelometric and tur-
bidimetric assays due to the native turbidity of the
sample. The Standard from Röche used on the Cobas
MIRA gave a non-linear dilution curve for apolipo-
protein A-I in the immunoluminometric assay, and va-
lues which were up to three times too low, when com-
pared with those from the Standard from Immuno (data
not presented here).
The non-standardisation of methods for the apolipo-
proteins limits the comparability of results obtained by
different methods, so that the value of mäny studies
must be questioned. Even with the introduction of an
international Standard for apolipoprotein A-I and apo-
lipoprotein B (18-20) it is not to be expected the inter-
method comparison will be better. This has been shown
repeatedly, especially for proteohormones and polypep-
tides. In the comparison of 29 methods for apolipo-
protein A-I using the proposed new international Stan-
dard (20) it was explicitly stated that the values assigned
by companies to their secondary Standards only holds
for the system used. Any change in the System may give
rise to other values (20). This shows the limits of stan-
dardisation by use of a common antigen. Twenty-eight
of the 29 methods used in this study to determine apo-
lipoprotein A-I were one-site competitive turbidimetric
or nephelometric methods, the remaining assay using
radial immunodiffusion. It should be noted, the latter
assay gave results which deviated most and had the low-
est correlation coefficient
The results for apolipoprotein C-II could not be com-
pared with another method äs none was available. An
indirect confirmation that the assay measured in the ex-
pected ränge was provided by reference ranges for apo-
lipoprotein C-II (30-80 mg/1) from other sources (26,
27). In this study, the median concfentration of 176 dialy-
sis patient samples was 30 mg/1 (ränge 4.1-176 mg/1).
The median concentration of 100 non-lipaemic serum
samples from healthy adults was 37 mg/1 (ränge 9.6-
85 mg/1). There was no sex-linked difference. This re-
presented the amount of apolipoprotein C-II complexed
with apolipoprotein B; it was not possible to set up an
immunometric method for apolipoprotein C-II alone.
The lower values may be due to the incomplete determi-
nation of apolipoprotein , i. e. that not complexed
with apolipoprotein B, or to the specificity of the sand-
wich method or the Standard used. The method and re-
sults for apolipoprotein C-II:B complexes have been in-
cluded to show that it is possible to measure apolipo-
protein complexes. Although this assay is of miiiimum
routine use, it may be of interest in those centres con-
ceraed with diagnosis of lipoprotein äbnormalities, es-
pecially in renal dialysis patients, many of whom are
known to have severe lipid disorders.
This short communication is intended to demonstrate the
use of robust and reliable immunometric methodology
in the field of lipid metabolism, especially where large
numbers of samples can be analysed economically using
commercially available reagents not in kit form. Such
assays provide consistent results over a long period, pro-
vided sufficient antisera is purchased. This is especially
important in long-term epidemiological studies, where
methodological Variation must be excluded for an opti-
mal Interpretation of the data obtained.
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